key: cord-0741482-sz3mh3rd
authors: Jordan, Stanley C; Zakowski, Phillip; Tran, Hai P; Smith, Ethan A; Gaultier, Cyril; Marks, Gregory; Zabner, Rachel; Lowenstein, Hayden; Oft, Jillian; Bluen, Benjamin; Le, Catherine; Shane, Rita; Ammerman, Noriko; Vo, Ashley; Chen, Peter; Kumar, Sanjeev; Toyoda, Mieko; Ge, Shili; Huang, Edmund
title: Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
date: 2020-06-23
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa812
sha: 18fdcf1a4b55d6b4fd0e275c59ec05394437de3c
doc_id: 741482
cord_uid: sz3mh3rd

BACKGROUND: Preliminary data from SARS-CoV-2 pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is FDA-approved for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia. METHODS: We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations <90% on oxygen support with most intubated. We examined clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment. RESULTS: Twenty seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. IL-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post-tocilizumab. However, four patients did not show rapid CRP declines, of whom three had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but two deaths (7.4%) occurred that were felt unrelated to tocilizumab. CONCLUSIONS: Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.

A c c e p t e d M a n u s c r i p t Introduction:

The COVID-19 epidemic is rapidly consuming the world. As of April 15, 2020, there are more than two million cases worldwide with 133,277 deaths 1 . In the United States, the epidemic is rapidly spreading with increasing numbers of confirmed cases and deaths. Initial data from China suggests the primary mortality risk of COVID-19 is attributable to severe pneumonia from the SARS-CoV-2 virus that leads to acute respiratory distress syndrome (ARDS), which is reported to have a mortality of 60.5% [2] [3] [4] . The COVID-19 epidemic has shut down most of the world and is decimating the world's economies. Vaccines are being developed but are unlikely to be deployed in the near future. There is a clear and prescient need for new drug development to help save lives and our economies. Although promising agents are being tested in clinical trials, most studies to date are anecdotal and of unclear benefit.

ARDS is a syndrome that causes acute hypoxemic respiratory failure often resulting in mechanical ventilation 5 . The etiology of ARDS is diverse and can include pulmonary (e.g., bacterial and viral pneumonia) and extra-pulmonary (e.g., sepsis, blood transfusions) causes. Those with severe disease can have a mortality A c c e p t e d M a n u s c r i p t rate as high as 45% 6 . The lung injury of ARDS induces a number of inflammatory cytokines that can cause both local and distal organ damage, and this dysregulated inflammation is a primary driver of the disease [7] [8] [9] .

Interleukin 6 (IL-6) is a cytokine critical to the function of innate and adaptive immunity. IL-6 has diverse immunologic and physiologic activities including the direction of immune cell differentiation and initial responses to invading pathogens and ischemic injury. IL-6 transcriptional dysregulation is often seen in patients with autoimmune and inflammatory disorders, including capillary leak syndrome and macrophage activating syndrome 10 . IL-6 has also been found to be elevated in ARDS and is predictive of poorer outcomes 11, 12 . Emerging information also suggests IL-6 transcriptional dysregulation is present in patients with infection and the extremes of IL-6 production are associated with and highly predictive of increased severity of disease and progression to ARDS from SARS-CoV-2 pneumonia [13] [14] [15] .

Tocilizumab (Actemra®, Roche/Genentech, CA, USA) is the first in class humanized monoclonal antibody aimed at the IL-6 receptor (IL-6R) and functions by binding to both soluble and membrane-bound forms of the IL-6R receptor and is approved by the FDA for the treatment of rheumatoid arthritis (RA) and juvenile A c c e p t e d M a n u s c r i p t idiopathic arthritis and cytokine release syndrome (CRS) 16 . In patients with CRS after chimeric antigen receptor (CAR) T-cell therapy, elevations of IL-6 and Creactive protein (CRP) can be seen that predict the severity of disease. Tocilizumab has an important and significant benefit in treating patients with CRS. The question is whether this benefit would translate to other diseases where extreme elevations of IL-6 and CRP are seen, such as COVID-19. Here, we report our experience using tocilizumab in patients with severe SARS-CoV-2 pneumonia. (Figure 1 and Table 2 ). 

The cytokine profile for all patients at time of tocilizumab administration is shown in figure 3a . The predominant cytokine seen in all patients was IL-6 with significantly higher levels compared to all other cytokines, (mean 356.07 ± 616 pg/mL, normal 0-5 pg/mL, p<0.001). Modest elevations were seen in -IFN and IL-10 but not to the degree seen with IL-6. Post-tocilizumab cytokine levels were not routinely obtained in these patients due to the known ability of tocilizumab to increase circulating IL-6 levels due to blocking IL-6's ability to bind to cellular IL-A c c e p t e d M a n u s c r i p t 6 receptor -and stabilizing IL-6/IL-6R complexes in the circulation 17 .

Here, the best way to assess the efficacy of inhibition of IL-6/IL-6R blockade by tocilizumab is to measure CRP. This data is shown in figure 3b . interest as a potential therapy in the battle against the severe and often fatal pneumonia seen in SARS-CoV-2 patients due to its known efficacy in treating cytokine storm associated with CAR T-cell therapy 19 . In addition, several case reports have shown encouraging results [20] [21] [22] .

Based on these observations and our own experience with tocilizumab for other indications, we undertook a compassionate use study to determine if patients with SARS-CoV-2 pneumonia would benefit from early tocilizumab administration.

Data presented here indicate that IL-6 was the predominant cytokine elevated at The primary limitation of this study is the absence of a control group.

Additionally, due to drug shortages, we used a single 400 mg (one vial) dose of tocilizumab, which is lower than the recommended dose of 8 mg/kg for CRS. Our The impact of these treatments on the outcomes observed in this study is not known, particularly because prior reports have not uniformly found these treatments to be beneficial [24] [25] [26] .

In summary, our early experience with tocilizumab suggests that targeted treatment against cytokine storm related to SARS-CoV2 infection may lead to clinical improvement, recovery from respiratory failure, and prevention of death. Despite these encouraging results, we are mindful that proof of efficacy awaits results from A c c e p t e d M a n u s c r i p t a placebo controlled trial (Roche-Genentech) that is now underway. However, we continue to offer tocilizumab to patients admitted with SARS-CoV-2 pneumonia based on these preliminary results.

A c c e p t e d M a n u s c r i p t Acknowledgements:

We want to express our gratitude to the nurses, physicians, respiratory therapist, social workers, laboratorians, and support staff whose dedication and devotion to our patients is exemplary. We also want to acknowledge and thank the patients who participated in this study. Finally, we remember all those who have perished from COVID-19, our thoughts and prayers are with them and their families. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Inferior allograft outcomes in adolescent recipients of renal transplants from ideal deceased donors

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series. The New England journal of medicine

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Acute Respiratory Distress Syndrome. The New England journal of medicine

Acute respiratory distress syndrome: the Berlin Definition

Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental

Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial

Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade

Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury

Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

COVID-19: consider cytokine storm syndromes and immunosuppression

Interleukin-6 as a potential biomarker of COVID-19 progression

Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

Biliary and Urinary Excretion of Porphyrins in the Rat Studied by Intravital Fluorescence Microscopy

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Reevaluation of the Kidney Donor Risk Index

Validation of the Prognostic Kidney Donor Risk Index Scoring System of Deceased Donors for Renal Transplantation in the Netherlands

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report

SARS-Cov-2 in Spanish Intensive Care: Early Experience with 15-day Survival In Vitoria

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

A c c e p t e d M a n u s c r i p t